Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution
Background Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution. Method A total of 170 consecutive patients underwent CRS-HIPEC for peri...
Gespeichert in:
| Veröffentlicht in: | Journal of gastrointestinal surgery 2014-05, Vol.18 (5), p.1024-1031 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1031 |
|---|---|
| container_issue | 5 |
| container_start_page | 1024 |
| container_title | Journal of gastrointestinal surgery |
| container_volume | 18 |
| creator | Tabrizian, Parissa Shrager, Brian Jibara, Ghalib Yang, Ming-Jim Romanoff, Anya Hiotis, Spiros Sarpel, Umut Labow, Daniel M. |
| description | Background
Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution.
Method
A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between July 2007 and August 2012. The peritoneal cancer index (1–39) was used for peritoneal carcinomatosis (PC) staging. Mitomycin C (88.8 %) was administered intraperitoneally at 42 °C for 90 mins. Risk factors associated with major morbidities were analyzed. The Kaplan-Meier method was used for survival analyses.
Results
The mean age was 55.1 (±11.3) years, and the majority (77.1 %) of patients had complete cytoreduction (CC0-1). Tumor types included colorectal (
n
= 51, 30.0 %), appendiceal (
n
= 50, 29.4 %), pseudomyxoma peritonei (
n
= 16, 9.4 %), and other (
n
= 53, 31.2 %). Factors associated with major complications were estimated blood loss (>400 ml), length of stay (>1 week), intraoperative blood transfusion, operative time (>6 h), and bowel anastomosis. Intraoperative blood transfusion was the only independent prognostic factor on multivariate analysis (
p
= 0.031). Median follow-up was 15.7 months (±1.2). The recurrence rates for colorectal and appendiceal carcinoma at 1 and 3 years were 40 %, 53.5 % and 68 %, 79.1 %, respectively. The 1- and 3-year overall survival for colorectal and appendiceal carcinomatosis was 74.0 %, 32.5 % and 89.4 %, 29.3 %, respectively. Intraoperative peritoneal cancer index (PCI) score (>16) and need for blood transfusion were factors independently associated with poor survival (
p
16 was associated with poor survival. This series supports the safety of CRS-HIPEC in selected patients. |
| doi_str_mv | 10.1007/s11605-014-2477-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1521897383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3296595221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-abcfa9d42544bf7dc6295329a008d7ccb606056863ca5d139161f4818260f7293</originalsourceid><addsrcrecordid>eNp1UctKBDEQDKL4_gAvEvA8mk4myYw3WXwsCAoqeAvZTEYjO8maZIT9Cb_ZLKvixVOnqeqqUIXQEZBTIESeJQBBeEWgrmgtZcU30C40klW1oGKzvEkLFeX8eQftpfRGCEgCzTbaoTWXUjKxiz4nyxyi7UaT3YfFD2N8sXGJte_wzXJhY361cXAGT32OuuwuB2_1HE9e7RBWoF4scR8ivv-D6WicD4POIbl0ju_GbMJgE-5jGLDGD86_zC1-LOpOF7OpT9nlMbvgD9BWr-fJHn7PffR0dfk4ualu766nk4vbyjBJc6VnptdtV1Ne17NedkbQljPaakKaThozE6QEIxrBjOYdsBYE9HUDDRWkl7Rl--hkrbuI4X20Kau3MEZfLBVwCk0rWcMKC9YsE0NK0fZqEd1QvqyAqFUDat2AKg2oVQOKl5vjb-VxNtju9-In8kKga0IqkC9p_7H-V_ULy4SUBA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1521897383</pqid></control><display><type>article</type><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Tabrizian, Parissa ; Shrager, Brian ; Jibara, Ghalib ; Yang, Ming-Jim ; Romanoff, Anya ; Hiotis, Spiros ; Sarpel, Umut ; Labow, Daniel M.</creator><creatorcontrib>Tabrizian, Parissa ; Shrager, Brian ; Jibara, Ghalib ; Yang, Ming-Jim ; Romanoff, Anya ; Hiotis, Spiros ; Sarpel, Umut ; Labow, Daniel M.</creatorcontrib><description>Background
Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution.
Method
A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between July 2007 and August 2012. The peritoneal cancer index (1–39) was used for peritoneal carcinomatosis (PC) staging. Mitomycin C (88.8 %) was administered intraperitoneally at 42 °C for 90 mins. Risk factors associated with major morbidities were analyzed. The Kaplan-Meier method was used for survival analyses.
Results
The mean age was 55.1 (±11.3) years, and the majority (77.1 %) of patients had complete cytoreduction (CC0-1). Tumor types included colorectal (
n
= 51, 30.0 %), appendiceal (
n
= 50, 29.4 %), pseudomyxoma peritonei (
n
= 16, 9.4 %), and other (
n
= 53, 31.2 %). Factors associated with major complications were estimated blood loss (>400 ml), length of stay (>1 week), intraoperative blood transfusion, operative time (>6 h), and bowel anastomosis. Intraoperative blood transfusion was the only independent prognostic factor on multivariate analysis (
p
= 0.031). Median follow-up was 15.7 months (±1.2). The recurrence rates for colorectal and appendiceal carcinoma at 1 and 3 years were 40 %, 53.5 % and 68 %, 79.1 %, respectively. The 1- and 3-year overall survival for colorectal and appendiceal carcinomatosis was 74.0 %, 32.5 % and 89.4 %, 29.3 %, respectively. Intraoperative peritoneal cancer index (PCI) score (>16) and need for blood transfusion were factors independently associated with poor survival (
p
< 0.05).
Conclusion
Our single institution experience of CRS/HIPEC procedures for peritoneal carcinomatosis demonstrates acceptable perioperative outcome and long-term survival. Optimal cytoreduction was achieved in the majority of cases. Intraoperative PCI > 16 was associated with poor survival. This series supports the safety of CRS-HIPEC in selected patients.</description><identifier>ISSN: 1091-255X</identifier><identifier>EISSN: 1873-4626</identifier><identifier>DOI: 10.1007/s11605-014-2477-5</identifier><identifier>PMID: 24577736</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject><![CDATA[Abdomen ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Appendiceal Neoplasms - pathology ; Blood Transfusion ; Blood transfusions ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Carcinoma - pathology ; Carcinoma - therapy ; Chemotherapy ; Colorectal cancer ; Colorectal Neoplasms - pathology ; Combined Modality Therapy ; Cytoreduction Surgical Procedures - adverse effects ; Female ; Gallbladder Neoplasms - pathology ; Gastroenterology ; Humans ; Hyperthermia, Induced ; Intraoperative Care ; Irinotecan ; Male ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Mitomycin - administration & dosage ; Morbidity ; Neoplasm Recurrence, Local - secondary ; Organoplatinum Compounds - administration & dosage ; Original Article ; Ovarian Neoplasms - pathology ; Oxaliplatin ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - therapy ; Pseudomyxoma Peritonei - therapy ; Stomach Neoplasms - pathology ; Surgery ; Survival Rate ; Tertiary Care Centers ; Transplants & implants ; Tumors]]></subject><ispartof>Journal of gastrointestinal surgery, 2014-05, Vol.18 (5), p.1024-1031</ispartof><rights>The Society for Surgery of the Alimentary Tract 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-abcfa9d42544bf7dc6295329a008d7ccb606056863ca5d139161f4818260f7293</citedby><cites>FETCH-LOGICAL-c372t-abcfa9d42544bf7dc6295329a008d7ccb606056863ca5d139161f4818260f7293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11605-014-2477-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11605-014-2477-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24577736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tabrizian, Parissa</creatorcontrib><creatorcontrib>Shrager, Brian</creatorcontrib><creatorcontrib>Jibara, Ghalib</creatorcontrib><creatorcontrib>Yang, Ming-Jim</creatorcontrib><creatorcontrib>Romanoff, Anya</creatorcontrib><creatorcontrib>Hiotis, Spiros</creatorcontrib><creatorcontrib>Sarpel, Umut</creatorcontrib><creatorcontrib>Labow, Daniel M.</creatorcontrib><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution</title><title>Journal of gastrointestinal surgery</title><addtitle>J Gastrointest Surg</addtitle><addtitle>J Gastrointest Surg</addtitle><description>Background
Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution.
Method
A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between July 2007 and August 2012. The peritoneal cancer index (1–39) was used for peritoneal carcinomatosis (PC) staging. Mitomycin C (88.8 %) was administered intraperitoneally at 42 °C for 90 mins. Risk factors associated with major morbidities were analyzed. The Kaplan-Meier method was used for survival analyses.
Results
The mean age was 55.1 (±11.3) years, and the majority (77.1 %) of patients had complete cytoreduction (CC0-1). Tumor types included colorectal (
n
= 51, 30.0 %), appendiceal (
n
= 50, 29.4 %), pseudomyxoma peritonei (
n
= 16, 9.4 %), and other (
n
= 53, 31.2 %). Factors associated with major complications were estimated blood loss (>400 ml), length of stay (>1 week), intraoperative blood transfusion, operative time (>6 h), and bowel anastomosis. Intraoperative blood transfusion was the only independent prognostic factor on multivariate analysis (
p
= 0.031). Median follow-up was 15.7 months (±1.2). The recurrence rates for colorectal and appendiceal carcinoma at 1 and 3 years were 40 %, 53.5 % and 68 %, 79.1 %, respectively. The 1- and 3-year overall survival for colorectal and appendiceal carcinomatosis was 74.0 %, 32.5 % and 89.4 %, 29.3 %, respectively. Intraoperative peritoneal cancer index (PCI) score (>16) and need for blood transfusion were factors independently associated with poor survival (
p
< 0.05).
Conclusion
Our single institution experience of CRS/HIPEC procedures for peritoneal carcinomatosis demonstrates acceptable perioperative outcome and long-term survival. Optimal cytoreduction was achieved in the majority of cases. Intraoperative PCI > 16 was associated with poor survival. This series supports the safety of CRS-HIPEC in selected patients.</description><subject>Abdomen</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Appendiceal Neoplasms - pathology</subject><subject>Blood Transfusion</subject><subject>Blood transfusions</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - therapy</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures - adverse effects</subject><subject>Female</subject><subject>Gallbladder Neoplasms - pathology</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Intraoperative Care</subject><subject>Irinotecan</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mitomycin - administration & dosage</subject><subject>Morbidity</subject><subject>Neoplasm Recurrence, Local - secondary</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Original Article</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Oxaliplatin</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Pseudomyxoma Peritonei - therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Tertiary Care Centers</subject><subject>Transplants & implants</subject><subject>Tumors</subject><issn>1091-255X</issn><issn>1873-4626</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1UctKBDEQDKL4_gAvEvA8mk4myYw3WXwsCAoqeAvZTEYjO8maZIT9Cb_ZLKvixVOnqeqqUIXQEZBTIESeJQBBeEWgrmgtZcU30C40klW1oGKzvEkLFeX8eQftpfRGCEgCzTbaoTWXUjKxiz4nyxyi7UaT3YfFD2N8sXGJte_wzXJhY361cXAGT32OuuwuB2_1HE9e7RBWoF4scR8ivv-D6WicD4POIbl0ju_GbMJgE-5jGLDGD86_zC1-LOpOF7OpT9nlMbvgD9BWr-fJHn7PffR0dfk4ualu766nk4vbyjBJc6VnptdtV1Ne17NedkbQljPaakKaThozE6QEIxrBjOYdsBYE9HUDDRWkl7Rl--hkrbuI4X20Kau3MEZfLBVwCk0rWcMKC9YsE0NK0fZqEd1QvqyAqFUDat2AKg2oVQOKl5vjb-VxNtju9-In8kKga0IqkC9p_7H-V_ULy4SUBA</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Tabrizian, Parissa</creator><creator>Shrager, Brian</creator><creator>Jibara, Ghalib</creator><creator>Yang, Ming-Jim</creator><creator>Romanoff, Anya</creator><creator>Hiotis, Spiros</creator><creator>Sarpel, Umut</creator><creator>Labow, Daniel M.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20140501</creationdate><title>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution</title><author>Tabrizian, Parissa ; Shrager, Brian ; Jibara, Ghalib ; Yang, Ming-Jim ; Romanoff, Anya ; Hiotis, Spiros ; Sarpel, Umut ; Labow, Daniel M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-abcfa9d42544bf7dc6295329a008d7ccb606056863ca5d139161f4818260f7293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Appendiceal Neoplasms - pathology</topic><topic>Blood Transfusion</topic><topic>Blood transfusions</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - therapy</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures - adverse effects</topic><topic>Female</topic><topic>Gallbladder Neoplasms - pathology</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Intraoperative Care</topic><topic>Irinotecan</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mitomycin - administration & dosage</topic><topic>Morbidity</topic><topic>Neoplasm Recurrence, Local - secondary</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Original Article</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Oxaliplatin</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Pseudomyxoma Peritonei - therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Tertiary Care Centers</topic><topic>Transplants & implants</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tabrizian, Parissa</creatorcontrib><creatorcontrib>Shrager, Brian</creatorcontrib><creatorcontrib>Jibara, Ghalib</creatorcontrib><creatorcontrib>Yang, Ming-Jim</creatorcontrib><creatorcontrib>Romanoff, Anya</creatorcontrib><creatorcontrib>Hiotis, Spiros</creatorcontrib><creatorcontrib>Sarpel, Umut</creatorcontrib><creatorcontrib>Labow, Daniel M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Journal of gastrointestinal surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tabrizian, Parissa</au><au>Shrager, Brian</au><au>Jibara, Ghalib</au><au>Yang, Ming-Jim</au><au>Romanoff, Anya</au><au>Hiotis, Spiros</au><au>Sarpel, Umut</au><au>Labow, Daniel M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution</atitle><jtitle>Journal of gastrointestinal surgery</jtitle><stitle>J Gastrointest Surg</stitle><addtitle>J Gastrointest Surg</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>18</volume><issue>5</issue><spage>1024</spage><epage>1031</epage><pages>1024-1031</pages><issn>1091-255X</issn><eissn>1873-4626</eissn><abstract>Background
Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution.
Method
A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between July 2007 and August 2012. The peritoneal cancer index (1–39) was used for peritoneal carcinomatosis (PC) staging. Mitomycin C (88.8 %) was administered intraperitoneally at 42 °C for 90 mins. Risk factors associated with major morbidities were analyzed. The Kaplan-Meier method was used for survival analyses.
Results
The mean age was 55.1 (±11.3) years, and the majority (77.1 %) of patients had complete cytoreduction (CC0-1). Tumor types included colorectal (
n
= 51, 30.0 %), appendiceal (
n
= 50, 29.4 %), pseudomyxoma peritonei (
n
= 16, 9.4 %), and other (
n
= 53, 31.2 %). Factors associated with major complications were estimated blood loss (>400 ml), length of stay (>1 week), intraoperative blood transfusion, operative time (>6 h), and bowel anastomosis. Intraoperative blood transfusion was the only independent prognostic factor on multivariate analysis (
p
= 0.031). Median follow-up was 15.7 months (±1.2). The recurrence rates for colorectal and appendiceal carcinoma at 1 and 3 years were 40 %, 53.5 % and 68 %, 79.1 %, respectively. The 1- and 3-year overall survival for colorectal and appendiceal carcinomatosis was 74.0 %, 32.5 % and 89.4 %, 29.3 %, respectively. Intraoperative peritoneal cancer index (PCI) score (>16) and need for blood transfusion were factors independently associated with poor survival (
p
< 0.05).
Conclusion
Our single institution experience of CRS/HIPEC procedures for peritoneal carcinomatosis demonstrates acceptable perioperative outcome and long-term survival. Optimal cytoreduction was achieved in the majority of cases. Intraoperative PCI > 16 was associated with poor survival. This series supports the safety of CRS-HIPEC in selected patients.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24577736</pmid><doi>10.1007/s11605-014-2477-5</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1091-255X |
| ispartof | Journal of gastrointestinal surgery, 2014-05, Vol.18 (5), p.1024-1031 |
| issn | 1091-255X 1873-4626 |
| language | eng |
| recordid | cdi_proquest_journals_1521897383 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Abdomen Adult Aged Antineoplastic Combined Chemotherapy Protocols Appendiceal Neoplasms - pathology Blood Transfusion Blood transfusions Camptothecin - administration & dosage Camptothecin - analogs & derivatives Carcinoma - pathology Carcinoma - therapy Chemotherapy Colorectal cancer Colorectal Neoplasms - pathology Combined Modality Therapy Cytoreduction Surgical Procedures - adverse effects Female Gallbladder Neoplasms - pathology Gastroenterology Humans Hyperthermia, Induced Intraoperative Care Irinotecan Male Medicine Medicine & Public Health Metastasis Middle Aged Mitomycin - administration & dosage Morbidity Neoplasm Recurrence, Local - secondary Organoplatinum Compounds - administration & dosage Original Article Ovarian Neoplasms - pathology Oxaliplatin Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Pseudomyxoma Peritonei - therapy Stomach Neoplasms - pathology Surgery Survival Rate Tertiary Care Centers Transplants & implants Tumors |
| title | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Outcomes from a Single Tertiary Institution |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A15%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoreductive%20Surgery%20and%20Hyperthermic%20Intraperitoneal%20Chemotherapy%20for%20Peritoneal%20Carcinomatosis:%20Outcomes%20from%20a%20Single%20Tertiary%20Institution&rft.jtitle=Journal%20of%20gastrointestinal%20surgery&rft.au=Tabrizian,%20Parissa&rft.date=2014-05-01&rft.volume=18&rft.issue=5&rft.spage=1024&rft.epage=1031&rft.pages=1024-1031&rft.issn=1091-255X&rft.eissn=1873-4626&rft_id=info:doi/10.1007/s11605-014-2477-5&rft_dat=%3Cproquest_cross%3E3296595221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1521897383&rft_id=info:pmid/24577736&rfr_iscdi=true |